Multiplex Assays Market

The global multiplex assay market is projected to reach USD 10.65 billion by 2031 from USD 7.15 billion in 2026, at a CAGR of 8.3%. The adoption of multiplex assays is evolving against the backdrop of practical advances in laboratory practices, amid growing testing volumes, shortened turnaround times, and increasingly complex biological disease mechanisms. High demand is driven by the need to test multiple biomarkers on a single sample, particularly in oncology, respiratory illnesses, and decision-making. Equally significant, there is mounting pressure on laboratories to increase efficiency by reducing labor, making multiplex automation economically viable. There have been positive developments in reimbursement policies that favor multiplex tests in some geographic areas, thereby facilitating the transition away from traditional single-biomarker platforms. In addition, a lack of samples for analysis can create opportunities for multiplex technology in pediatrics and intensive care.

The competitive landscape of the multiplex assay industry continues to be dominated by well-known diagnostic firms and life sciences companies, including Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), DiaSorin S.p.A. (Italy), and bioMérieux SA (France), among others. The current competition among businesses focuses on offering broader test menus, a larger installed base of instruments, and the ability to shorten validation periods for laboratories. Several companies are focusing their efforts on research and development to develop more sensitive multiplex PCR testing, immunoassay testing, and sequencing that are fast and produce clean output. In today’s environment, regulatory clearances serve as commercial drivers, facilitating quicker distributor partnerships and reimbursement options than sales growth alone would permit.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific Inc. (US) is a key player in the multiplex assay industry due to its extensive product portfolio, global operations, and ongoing innovations in molecular diagnostics. It spans all major healthcare and research industries worldwide, providing it with a wide customer base and high recurring sales of consumables. Its Biosciences division and Analytical Instruments segment have provided it with a robust base for developing multiplex PCR, immunoassays, and genomics-based tests. Its growth through acquisitions has further enhanced its competencies, with goodwill on its balance sheet totaling approximately USD 49.36 billion. In April 2026, it introduced the Applied Biosystems PowerFlex Thermal Cycler, a 3x32-well Veriflex-based thermal cycler that enables simultaneous multiplex assays.

Illumina, Inc. (US)

Illumina is a major player due to its position in sequencing and array solutions in genomics and genetics. Products and services offered by the company cater to diverse markets and enable the use of genomic technology in cancer treatments, fertility studies, infectious disease tests, and precision medicine. It has a vast installed base with a presence across different parts of the world, which contributes to sustained demand for reagents, software, and workflows. By December 28, 2025, Illumina had acquired ownership of or exclusive licenses to 1,380 US patents and 1,120 US patent applications. The company reported R&D expenses amounting to USD 967 million in 2025. The collaboration between Illumina and LabCorp Holdings Inc. was furthered in March 2026 to develop and commercialize multiplex oncology next-generation sequencing tests, including CGP, liquid biopsy, and whole-genome sequencing tests.

Market Ranking

Thermo Fisher Scientific Inc. (US) is a key player in the multiplex assay segment, owing to its wide array of PCR instruments, immunoassay platforms, reagents, and laboratory automation solutions. Illumina Inc. (US) dominates the market through innovative multiplexing technology based on next-generation sequencing methods applied for oncology profiling, inherited disorders, and precision medicine. DiaSorin S.p.A. (Italy) is another major participant with a comprehensive menu of molecular diagnostics assays and multiplex testing systems for the identification of infectious diseases. The company enjoys the advantage of global distribution capability and continuous consumption of consumable products in its Favor. In contrast, Illumina is a leading company in the field of genomics multiplexing technology innovation.

Related Reports:

Multiplex Assays Market by Product & Service (Consumable, Instrument), Type (Protein, Nucleic Acid), Technology (Flow Cytometry), Application [R&D, Diagnostics (Infectious Disease, Cancer)], End User (Hospital, Research Institute)-Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]